Recruiting |
Study Name: Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2016-03-15
Interventions: - Drug: Carboplatin Given IV
|
Recruiting |
Study Name: Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2016-07-29
Interventions: - Biological: Bevacizumab Given
|
Not yet recruiting |
Study Name: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2016-07-20
Interventions: - Drug: Atezolizumab Given IV
|
Active, not recruiting |
Study Name: Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2010-02-23
Interventions: - Drug: Bortezomib Given IP
|
Active, not recruiting |
Study Name: Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2009-04-24
Interventions: - Drug: Elesclomol Sodium Given
|
Recruiting |
Study Name: Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2008-07-18
Interventions: - Behavioral: Behavioral Dietary Intervention
|
Completed |
Study Name: Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2005-12-06
Interventions: - Biological: Bevacizumab Given
|
Active, not recruiting |
Study Name: Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer
Condition: - Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endomet
Date: 2005-04-18
Interventions: - Other: Clinical Observation Un
|
Active, not recruiting |
Study Name: Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Fallopian Tube Carcinosarcoma
- Fallopian Tube Clear Cell Adenocarcinoma
Date: 2009-10-02
Interventions: - Biological: Bevacizumab Given
|
Recruiting |
Study Name: Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: - Deleterious BRCA1 Gene Mutation
- Deleterious BRCA2 Gene Mutation
-
- Drug: Cediranib Maleate Given
|